Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2014 2
2016 7
2017 27
2018 25
2019 28
2020 12
2021 13
2022 2
2023 6
2024 3
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Olaratumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999955 Free Books & Documents. Review.
Olaratumab is no longer marketed in the United States. No information is available on the clinical use of olaratumab during breastfeeding. ...The manufacturer recommends that women should not breastfeed during treatment with olaratumab and for 3 months follow …
Olaratumab is no longer marketed in the United States. No information is available on the clinical use of olaratumab during br …
Olaratumab: First Global Approval.
Shirley M. Shirley M. Drugs. 2017 Jan;77(1):107-112. doi: 10.1007/s40265-016-0680-2. Drugs. 2017. PMID: 27995580 Review.
Olaratumab (Lartruvo ) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor alpha (PDGFRalpha). ...In addition, the EMA granted conditional approval for olaratumab in this indication in November 2016 fol …
Olaratumab (Lartruvo ) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) rec …
Lixisenatide.
Baker DE, Levien TL. Baker DE, et al. Hosp Pharm. 2017 Jan;52(1):65-80. doi: 10.1310/hpj5201-65. Hosp Pharm. 2017. PMID: 28179743 Free PMC article.
The January 2017 monograph topics are bezlotoxumab, buprenorphine buccal, deflazacort, dupilumab, and olaratumab. The DUE is on buprenorphine buccal....
The January 2017 monograph topics are bezlotoxumab, buprenorphine buccal, deflazacort, dupilumab, and olaratumab. The DUE is on bupre …
Olaratumab.
[No authors listed] [No authors listed] 2017 May 29. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 May 29. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644245 Free Books & Documents. Review.
Olaratumab is a human monoclonal antibody to the platelet-derived growth factor (PDGF) receptor alpha and an antineoplastic agent used in the therapy of advanced soft tissue sarcoma. Olaratumab has not been linked to serum enzyme elevations during therapy or to idio …
Olaratumab is a human monoclonal antibody to the platelet-derived growth factor (PDGF) receptor alpha and an antineoplastic agent use …
Olaratumab for the treatment of soft-tissue sarcoma.
Pender A, Jones RL. Pender A, et al. Future Oncol. 2017 Oct;13(24):2151-2157. doi: 10.2217/fon-2017-0210. Epub 2017 Jul 26. Future Oncol. 2017. PMID: 28745071 Review.
A Phase Ib/randomized Phase II trial of doxorubicin with or without the monoclonal antibody to PDGFR-alpha, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. ...In this review, we describe some of the precli …
A Phase Ib/randomized Phase II trial of doxorubicin with or without the monoclonal antibody to PDGFR-alpha, olaratumab, demonstrated …
Olaratumab in soft tissue sarcoma - Current status and future perspectives.
Antoniou G, Lee ATJ, Huang PH, Jones RL. Antoniou G, et al. Eur J Cancer. 2018 Mar;92:33-39. doi: 10.1016/j.ejca.2017.12.026. Epub 2018 Feb 3. Eur J Cancer. 2018. PMID: 29413687 Free article. Review.
However, this result was disproportionate with progression-free survival and response rate, and consequently there are unanswered questions regarding the precise mechanism of action of olaratumab. While preclinical data show that olaratumab specifically inhibits PDG …
However, this result was disproportionate with progression-free survival and response rate, and consequently there are unanswered questions …
Pharmaceutical Approval Update.
Choy M. Choy M. P T. 2017 Jan;42(1):17-18. P T. 2017. PMID: 28090157 Free PMC article.
Olaratumab (Lartruvo) for the treatment of soft tissue sarcoma; bezlotoxumab (Zinplava) for use with an antibiotic to reduce recurrence of C. difficile infection; and doxylamine succinate/pyridoxine hydrochloride (Bonjesta) for the treatment of nausea and vomiting during p …
Olaratumab (Lartruvo) for the treatment of soft tissue sarcoma; bezlotoxumab (Zinplava) for use with an antibiotic to reduce recurren …
Olaratumab for soft tissue sarcoma.
Teyssonneau D, Italiano A. Teyssonneau D, et al. Expert Opin Biol Ther. 2017 Aug;17(8):1019-1025. doi: 10.1080/14712598.2017.1339031. Epub 2017 Jul 10. Expert Opin Biol Ther. 2017. PMID: 28691538 Review.
PDGFR-alpha and its ligand may play an important role in tumorigenesis and be a potential target in the treatment of sarcomas. Olaratumab is a fully human IgG1-type anti-PDGFR-alpha monoclonal antibody with a high affinity and a low 50% inhibitory concentration (IC50). Are …
PDGFR-alpha and its ligand may play an important role in tumorigenesis and be a potential target in the treatment of sarcomas. Olaratumab …
Olaratumab for advanced soft tissue sarcoma.
Tobias A, O'brien MP, Agulnik M. Tobias A, et al. Expert Rev Clin Pharmacol. 2017 Jul;10(7):699-705. doi: 10.1080/17512433.2017.1324295. Epub 2017 May 5. Expert Rev Clin Pharmacol. 2017. PMID: 28447475 Review.
Olaratumab is a humanized IgG1 monoclonal antibody that blocks the platelet-derived growth factor receptor alpha (PDGFRalpha). ...Expert commentary: The combination of olaratumab plus doxorubicin has provided a new front-line therapeutic option for soft tissue sarco …
Olaratumab is a humanized IgG1 monoclonal antibody that blocks the platelet-derived growth factor receptor alpha (PDGFRalpha). ...Exp …
Olaratumab: A Novel Platelet-Derived Growth Factor Receptor alpha-Inhibitor for Advanced Soft Tissue Sarcoma.
Andrick BJ, Gandhi A. Andrick BJ, et al. Ann Pharmacother. 2017 Dec;51(12):1090-1098. doi: 10.1177/1060028017723935. Epub 2017 Aug 4. Ann Pharmacother. 2017. PMID: 28778132 Review.
Trials of olaratumab for advanced soft tissue sarcomas were prioritized. DATA SYNTHESIS: Olaratumab is a human antiplatelet-derived growth factor receptor alpha monoclonal antibody. ...Additionally, overall survival was increased by 11.8 months in the olaratumab …
Trials of olaratumab for advanced soft tissue sarcomas were prioritized. DATA SYNTHESIS: Olaratumab is a human antiplatelet-de …
115 results